Summit Therapeutics
SMMT
17.95
+0.64
+3.70%
Summit Therapeutics
US · SMMT
#1207 by market cap
Listed 2015
17.95
+0.64
+3.70%
Live - 5344 symbols - heartbeat 138s ago
· 2026-10-08 06:49
Pre-market
17.80
-0.84%
After-hours
17.97
+0.11%
Overnight
17.71
-1.34%
- Market cap
- 14.32B
- P/E (TTM)i
- -16.17
- P/Bi
- 22.72
- EPSi
- -1.44
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on SMMT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 21.28% -0.25pp
- Institutions
- 287 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Individual/Insider76.88%
Mutual Fund8.64%
Hedge Fund7.22%
Public Company4.99%
Private Company0.18%
Sovereign Wealth Fund0.18%
Other1.85%
Top holders as of 2026-06-12
Robert Duggan
71.94% · 573.88M sh
Mahkam Zanganeh
4.53% · 36.13M sh
Baker Bros. Advisors LP
4.11% · 32.79M sh
Akeso, Inc.
4.02% · 32.06M sh
FMR
1.26% · 10.04M sh
State Street Global Advisors
1.20% · 9.54M sh
BlackRock
1.19% · 9.53M sh
Vanguard Capital Management, LLC
0.84% · 6.70M sh
UBS Asset Management
0.67% · 5.32M sh
Vanguard Portfolio Management, LLC
0.63% · 5.04M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 48 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Robert Duggan | Co-CEO & Executive Chairman | 71.94% |
| Mahkam Zanganeh | Co-Chief Executive Officer | 4.53% |
| Manmeet Soni | Chief Operating Officer | 0.39% |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance | 0.02% |
| Jeffrey Huber | Director | 0.01% |
| Kenneth Clark | Independent Non-Executive Director | -- |
| Robert F. Booth | Independent Director | -- |
| Mostafa Ronaghi | Director | -- |
| Alessandra Cesano | Independent Non-Executive Director | -- |
| Akeso, Inc. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-11 | Robert Duggan | Co-CEO & Executive Chairman | Open Market Acquisition | +3,810,000 | $13.12 |
| 2026-06-03 | Mahkam Zanganeh | Co-Chief Executive Officer | Open Market Acquisition | +100,000 | $14.60 |
| 2026-06-03 | Manmeet Soni | Chief Operating Officer | Open Market Acquisition | +50,000 | $14.43–14.46 |
| 2026-01-07 | Bhaskar Anand | Chief Accounting Officer & Head of Finance | Other Derivative Acquisition | +30,000 | $18.83 |
| 2026-01-01 | Kenneth Clark | Independent Non-Executive Director | Other Derivative Acquisition | +52,796 | $17.52 |
| 2026-01-01 | Robert F. Booth | Independent Director | Other Derivative Acquisition | +42,180 | $17.52 |
| 2026-01-01 | Robert Duggan | Co-CEO & Executive Chairman | Other Derivative Acquisition | +11,232 | $17.52 |
| 2026-01-01 | Jeffrey Huber | Director | Other Derivative Acquisition | +44,885 | $17.52 |
| 2026-01-01 | Mostafa Ronaghi | Director | Other Derivative Acquisition | +35,000 | $17.52 |
| 2026-01-01 | Mahkam Zanganeh | Co-Chief Executive Officer | Other Derivative Acquisition | +11,232 | $17.52 |
| 2026-01-01 | Alessandra Cesano | Independent Non-Executive Director | Other Derivative Acquisition | +38,219 | $17.52 |
| 2026-01-01 | Yu Xia | -- | Other Derivative Acquisition | +35,000 | $17.52 |
| 2025-10-20 | Robert Duggan | Co-CEO & Executive Chairman | Private Acquisition | +13,980,789 | $18.74 |
| 2025-10-20 | Mahkam Zanganeh | Co-Chief Executive Officer | Private Acquisition | +293,488 | $18.74 |
| 2025-10-20 | Manmeet Soni | Chief Operating Officer | Private Acquisition | +53,361 | $18.74 |
| 2025-10-20 | Akeso, Inc. | -- | Private Acquisition | +533,617 | $18.74 |
| 2025-10-20 | Bhaskar Anand | Chief Accounting Officer & Head of Finance | Private Acquisition | +26,680 | $18.74 |
| 2025-09-17 | Bhaskar Anand | Chief Accounting Officer & Head of Finance | Other Derivative Acquisition | +50,000 | $19.23 |
| 2025-09-10 | Robert Duggan | Co-CEO & Executive Chairman | Open Market Acquisition | +338,394 | $17.68–18.07 |
| 2025-05-29 | Robert Duggan | Co-CEO & Executive Chairman | Derivative Exercise and Retained | +74,545 | $2.64 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:49:11 · For reference only, not investment advice and not tailored to your situation.